A Dose-Finding Study of Nemiralisib Added to Standard of Care Versus Standard of Care Alone in Participants Diagnosed With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
This study will undertaken in COPD participants diagnosed with an acute moderate or severe exacerbation of COPD requiring treatment with SoC. Standard of Care (SoC) is defined as treatment with oral/systemic corticosteroids (prednisone 40mg/day or equivalent) for five days and antibiotics for seven days. Participants will be treated with nemiralisib or placebo in addition to SoC. The study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a range of doses compared with placebo for 12 weeks.